The development of continuous subcutaneous insulin infusion (CSII) pumps and short-acting insulin analogues exhibiting beneficial pharmacokinetic properties represents important advances in the treatment of diabetes and will be reviewed herein. This evidence concerns the gene INS and diabetes mellitus.